ethyl 3-[1-(4-chlorobenzyl)-3-(1,1-dimethylethylthio)-5-(pyrid-3-ylmethoxy)indol-2-yl]-2,2-dimethylpropionate | 154325-78-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 3-[1-(4-chlorobenzyl)-3-(1,1-dimethylethylthio)-5-(pyrid-3-ylmethoxy)indol-2-yl]-2,2-dimethylpropionate
• 英文别名: Ethyl 3-[1-(p-chlorobenzyl)-3-(1,1-dimethylethylthio)-5-(pyrid-3-ylmethoxy)indol-2-yl]-2,2-dimethylpropionate；ethyl 3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(pyridin-3-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoate
• CAS: 154325-78-7
• 化学式: C₃₂H₃₇ClN₂O₃S
• 分子量: 565.176
• InChiKey: PMILILYBLOWZIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  39
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  78.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 3-[1-(4-chlorobenzyl)-3-(1,1-dimethylethylthio)-5-(pyrid-3-ylmethoxy)indol-2-yl]-2,2-dimethylpropionate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成 3-[1-(4-chlorobenzyl)-3-(1,1-dimethylethylthio)-5-(pyrid-3-ylmethoxy)indol-2-yl]-2,2-dimethylpropionic acid
  参考文献：
  名称：

  O-alkylcarboxylate oxime and N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors

  摘要：

  Reference FLAP inhibitors 1 and 2 were converted into the corresponding O-acetic acid oxime congeners 8 and 11a, respectively, resulting in potent, orally active, leukotriene biosynthesis inhibitors. An attempt to create a dual FLAP and direct 5-LO inhibitor by replacing the carboxylate group in 1 with the N-hydroxyurea pharmacophore did not provide superior inhibitors. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00271-5
• 作为产物：
  描述：

  1-[(4-氯苯基)甲基]-3-[(1,1-二甲基乙基)硫基]-5-羟基-alpha,alpha-二甲基-1H-吲哚-2-丙酸乙酯 在 potassium carbonate 作用下， 以 N-甲基乙酰胺 、 乙醚 、 正己烷 为溶剂， 生成 ethyl 3-[1-(4-chlorobenzyl)-3-(1,1-dimethylethylthio)-5-(pyrid-3-ylmethoxy)indol-2-yl]-2,2-dimethylpropionate
  参考文献：
  名称：

  Indole carboxylate derivatives which inhibit leukotriene biosynthesis

  摘要：

  结构为##STR1##的化合物，其中A是直链或支链的二价烷基或二价环烷基，R.sub.1从氢；烷基硫代；可选择取代的苯硫代；可选择取代的苯基烷基硫代；可选择取代的2-，3-和4-吡啶基；可选择取代的2-和3-噻吩硫代；以及可选择取代的2-噻唑硫代中选择，R.sub.2从--COOB；--COO烷基；--COO烷基(碳环芳基)；--CONR.sub.5 R.sub.6 ；--COR.sub.6 ；和--OH中选择，R.sub.3从苯基烷基和杂环烷基烷基中选择，R.sub.4从可选择取代的烷氧基(碳环芳基)；可选择取代的碳环芳氧基；可选择取代的杂环烷基氧基；以及可选择取代的杂环氧基中选择，是脂氧合酶酶的有效抑制剂，从而抑制白三烯的生物合成。这些化合物在治疗或改善过敏和炎症性疾病状态中非常有用。

  公开号：

  US05288743A1

文献信息

• US5288743A
  申请人：——

  公开号：US5288743A

  公开（公告）日：1994-02-22
• Indole carboxylate derivatives which inhibit leukotriene biosynthesis
  申请人：Abbott Laboratories

  公开号：US05288743A1

  公开（公告）日：1994-02-22

  Compounds of the structure ##STR1## where A is straight or branched divalent alkylene or divalent cycloalkylene, R.sub.1 is selected from hydrogen; alkylthio; optionally substituted phenylthio; optionally substituted phenylalkylthio; optionally substituted 2-, 3-, and 4-pyridyl; optionally substituted 2-, and 3-thienylthio; and optionally substituted 2-thiazolythio, R.sub.2 is selected from --COOB; --COOalkyl; --COOalkyl(carbocyclic aryl); --CONR.sub.5 R.sub.6 ; --COR.sub.6 ; and --OH, R.sub.3 is selected from phenylalkyl and heteroarylalkyl, and R.sub.4 is selected from optionally substituted alkoxy(carbocyclic aryl); optionally substituted carbocyclic aryloxy; optionally substituted heteroarylalkoxy; and optionally substituted heteroaryloxy are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.

  结构为##STR1##的化合物，其中A是直链或支链的二价烷基或二价环烷基，R.sub.1从氢；烷基硫代；可选择取代的苯硫代；可选择取代的苯基烷基硫代；可选择取代的2-，3-和4-吡啶基；可选择取代的2-和3-噻吩硫代；以及可选择取代的2-噻唑硫代中选择，R.sub.2从--COOB；--COO烷基；--COO烷基(碳环芳基)；--CONR.sub.5 R.sub.6 ；--COR.sub.6 ；和--OH中选择，R.sub.3从苯基烷基和杂环烷基烷基中选择，R.sub.4从可选择取代的烷氧基(碳环芳基)；可选择取代的碳环芳氧基；可选择取代的杂环烷基氧基；以及可选择取代的杂环氧基中选择，是脂氧合酶酶的有效抑制剂，从而抑制白三烯的生物合成。这些化合物在治疗或改善过敏和炎症性疾病状态中非常有用。
• O-alkylcarboxylate oxime and N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors
  作者：Keith W. Woods、Clint D.W. Brooks、Robert G. Maki、Karen E. Rodriques、Jennifer B. Bouska、Patrick Young、Randy L. Bell、George W. Carter

  DOI：10.1016/s0960-894x(96)00271-5

  日期：1996.7

  Reference FLAP inhibitors 1 and 2 were converted into the corresponding O-acetic acid oxime congeners 8 and 11a, respectively, resulting in potent, orally active, leukotriene biosynthesis inhibitors. An attempt to create a dual FLAP and direct 5-LO inhibitor by replacing the carboxylate group in 1 with the N-hydroxyurea pharmacophore did not provide superior inhibitors. Copyright (C) 1996 Elsevier Science Ltd